Margaret von Mehren Selected Research

Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)

10/2021	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
3/2021	Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.
1/2021	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.
3/2018	Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.
1/2018	Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
1/2017	Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
11/2015	Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case.
6/2014	Gastrointestinal stromal tumors, version 2.2014.
7/2012	Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
11/2010	Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Margaret von Mehren Research Topics

Disease

68	Neoplasms (Cancer) 01/2022 - 08/2002
57	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2022 - 08/2002
27	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 03/2005
16	Disease Progression 11/2021 - 08/2008
13	Liposarcoma 01/2022 - 08/2005
9	Leiomyosarcoma 12/2019 - 12/2003
8	Fatigue 01/2022 - 08/2002
5	Nausea 01/2022 - 09/2009
4	Carcinogenesis 08/2017 - 05/2005
3	Anemia 11/2021 - 09/2009
3	Hypertension (High Blood Pressure) 01/2020 - 10/2012
3	Thrombocytopenia (Thrombopenia) 01/2017 - 10/2008
3	Neutropenia 05/2015 - 10/2008
3	Melanoma (Melanoma, Malignant) 09/2014 - 07/2010
3	Tetanus 07/2011 - 08/2008
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 06/2011 - 08/2002
2	Synovial Sarcoma (Synovioma) 01/2022 - 11/2015
2	Myxoid Liposarcoma 01/2022 - 10/2016
2	Abdominal Pain (Pain, Abdominal) 11/2021 - 03/2009
2	Hemangiosarcoma (Angiosarcoma) 09/2021 - 11/2015
2	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 05/2008
2	Aggressive Fibromatosis (Desmoid) 12/2020 - 08/2012
2	Diarrhea 10/2020 - 08/2002
2	Myalgia 10/2020 - 04/2007
2	Alopecia (Baldness) 10/2020 - 09/2009
2	Febrile Neutropenia 05/2015 - 11/2009
2	Leukemia 06/2013 - 11/2008
2	Fever (Fevers) 09/2009 - 04/2007
2	Colorectal Neoplasms (Colorectal Cancer) 08/2008 - 02/2005
1	Pneumonia (Pneumonitis) 01/2022
1	Pulmonary Embolism 01/2022
1	Extraskeletal Myxoid Chondrosarcoma 10/2021
1	Microsatellite Instability 09/2021
1	Constipation 10/2020
1	Acute Kidney Injury (Acute Renal Failure) 01/2020
1	Septic Shock (Toxic Shock Syndrome) 01/2020
1	Dehydration (Water Stress) 01/2020

Drug/Important Bio-Agent (IBA)

45	Imatinib Mesylate (Gleevec)FDA Link 01/2022 - 08/2002
15	Tyrosine Kinase InhibitorsIBA 12/2021 - 08/2002
12	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 10/2021 - 07/2003
12	Pharmaceutical PreparationsIBA 01/2021 - 06/2003
10	Phosphotransferases (Kinase)IBA 03/2021 - 12/2003
10	TrabectedinIBA 01/2021 - 10/2008
9	Sunitinib (Sutent)FDA Link 01/2018 - 12/2003
7	DNA (Deoxyribonucleic Acid)IBA 08/2017 - 05/2005
6	Dacarbazine (DIC)FDA LinkGeneric 12/2019 - 03/2016
6	Succinate Dehydrogenase (Fumarate Reductase)IBA 01/2018 - 01/2013
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2011
5	avapritinibIBA 01/2022 - 01/2021
5	ripretinibIBA 12/2021 - 01/2020
5	regorafenibIBA 10/2021 - 07/2012
5	Proteins (Proteins, Gene)FDA Link 03/2018 - 05/2005
5	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 08/2017 - 08/2002
4	Tyrosine (L-Tyrosine)FDA Link 03/2021 - 04/2004
4	VaccinesIBA 07/2011 - 02/2005
3	Dasatinib (BMS 354825)FDA Link 01/2018 - 03/2016
3	AnthracyclinesIBA 01/2017 - 09/2009
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/2015 - 10/2008
3	Telomerase (Telomerase Reverse Transcriptase)IBA 06/2013 - 08/2005
3	Insulin-Like PeptidesIBA 01/2013 - 06/2008
3	Aurora Kinase AIBA 09/2012 - 02/2011
3	Platelet-Derived Growth Factor alpha ReceptorIBA 10/2008 - 05/2005
3	Growth Factor ReceptorsIBA 07/2008 - 01/2003
2	tyrosine receptor (receptor, tyrosine)IBA 01/2021 - 01/2013
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2018 - 07/2008
2	EnzymesIBA 08/2017 - 11/2015
2	Alanine Transaminase (SGPT)IBA 05/2015 - 10/2008
2	AntibodiesIBA 09/2014 - 01/2003
2	Sorafenib (BAY 43-9006)FDA Link 08/2012 - 02/2012
2	Peptides (Polypeptides)IBA 07/2011 - 07/2010
2	nilotinib FDA Link 04/2011 - 09/2009
2	MLN8054IBA 04/2011 - 02/2011
2	Aurora KinasesIBA 02/2011 - 11/2009
2	AntigensIBA 07/2010 - 02/2005
2	Ifosfamide FDA LinkGeneric 03/2010 - 09/2009
2	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2010 - 10/2008
2	mapatumumabIBA 09/2009 - 04/2007
2	TOR Serine-Threonine KinasesIBA 08/2007 - 12/2003
1	atezolizumabIBA 01/2022
1	ponatinibIBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	selinexorIBA 01/2022
1	Circulating Tumor DNAIBA 12/2021
1	DesminIBA 10/2021
1	SynaptophysinIBA 10/2021
1	RNA (Ribonucleic Acid)IBA 10/2021
1	CAM 5.2 antigenIBA 10/2021
1	Tumor Biomarkers (Tumor Markers)IBA 09/2021
1	liposomal doxorubicin (Doxil)FDA Link 01/2021
1	Alkylating AgentsIBA 01/2021
1	Oncogene Proteins (Oncogene Protein)IBA 10/2020
1	Lipase (Acid Lipase)FDA Link 01/2020
1	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 01/2020

Therapy/Procedure

47	Therapeutics 01/2022 - 08/2002
17	Drug Therapy (Chemotherapy) 12/2019 - 08/2002
7	Radiotherapy 12/2020 - 05/2006
2	Neoadjuvant Therapy 01/2021 - 07/2008
1	Duration of Therapy 11/2021
1	Immunotherapy 09/2021
1	Nephrectomy 12/2019